Should you buy or sell the GSK share price?

Roland Head explains why big changes could make GlaxoSmithKline plc (LON: GSK) a compelling buy.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The GlaxoSmithKline (LSE: GSK) share price has beaten the market over the last five years, climbing 14% against a gain of less than 5% for the FTSE 100.

Since chief executive Emma Walmsley took charge in March 2017, she’s put in place a series of big changes that will lead to a completely reshaped business. As a shareholder myself, I feel good about the outlook for the business and believe these changes have made the stock much more attractive for new investors.

Big changes

When Walmsley took over as CEO, she appeared to support Glaxo’s conglomerate structure, which included pharmaceuticals, consumer healthcare products, and brands such as Horlicks.

At some point, Walmsley’s position changed. Horlicks has been sold to Unilever and the group’s consumer healthcare and pharmaceutical businesses are heading for a split by late 2022. Ahead of this split, both the pharma and consumer sides of the business are being bolstered by acquisitions to strengthen their long-term prospects.

US firm pharma Tesaro, which is focused on cancer treatments, was added to the Glaxo portfolio earlier this year for $5.1bn. In parallel with this, Walmsley agreed a series of deals with rivals Novartis and Pfizer that will significantly enlarge GSK’s consumer healthcare division.

With both parts of the business suitably reinforced, the stage has been set for Glaxo to split itself at some point in the next three years.

Why I think this is good news

Why do I think that splitting GSK into two will be good for shareholders? Two reasons. The first is that history suggests two smaller, more focused businesses perform better and attract higher valuations. That should be good for GSK shareholders, who will receive shares in the new consumer business.

The second reason I’m keen is that the split should help to solve Glaxo’s debt problem. The consumer healthcare business should benefit from predictable cash flows and stable profit margins. It should comfortably be able to take on a significant share of the group’s £29bn net debt. This should leave the pharma business with a stronger balance sheet and more flexibility to invest in new opportunities.

Focus on the numbers

Looking back at Glaxo’s accounts since 2016, I can see a clear pattern of improving profitability and stronger cash flow. My sums indicate GlaxoSmithKline’s operating profit margin has risen from a low of 9.3% in 2016 to 20.1% over the last 12 months.

Return on capital employed, which compares operating profit with capital invested in the business, has risen from 6.5% to 16.9% over the same period. In my view these are attractive figures which suggest the CEO has spent money wisely, and is returning the business to growth.

Is now the right time to buy GSK?

Glaxo’s rising share price means this stock isn’t quite as cheap as it was a few months ago. However, for long-term investors, I think the valuation remains attractive.

At the time of writing, GSK shares were trading on 14.6 times 2019 forecast earnings, with a dividend yield of 4.8%. I think that’s a reasonable starting point and would continue to rate Glaxo shares a ‘buy’.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black man looking at phone while on the London Overground
Value Shares

After a 16% drop, FTSE 100 stock JD Sports Fashion looks like a steal to me

This FTSE 100 stock has tanked since mid-September. Edward Sheldon believes that there's value on offer after the share price…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Is now the time to buy BP shares? Here’s what the charts say

The best time to buy shares in a company is when they’re trading at a discount. But the future is…

Read more »

Investing Articles

Here’s how I’d use £50K to aim for a million when the stock market crashes

Seeing a stock market crash as a buying opportunity could prove lucrative for a well-prepared, long-term investor. Christopher Ruane explains…

Read more »

Stack of one pound coins falling over
Investing Articles

It’s up 27% with a P/E of 9! I’m considering the potential of this blossoming penny stock

Despite several years of losses, this UK penny stock has an impressive valuation. I’m looking to see if it could…

Read more »

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »